A First-in-Human Trial of GDC-0068: A Novel, Oral, ATP-Competitive Akt Inhibitor, Demonstrates Robust Suppression of the Akt Pathway in Surrogate and Tumor Tissues


Abstract

GDC-­0068 demonstrates particularly robust activity in tumors with activation of the PI3K-­Akt-­mTOR pathway, through either loss of PTEN or mutations in PIK3CA, enabling a straightforward strategy to identify patients most likely to benefit.
Poster
non-peer-reviewed

A First-in-Human Trial of GDC-0068: A Novel, Oral, ATP-Competitive Akt Inhibitor, Demonstrates Robust Suppression of the Akt Pathway in Surrogate and Tumor Tissues


Author Information


PDF Share